The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy

Community Oncology

Volumn 8, Issue 11, 2011, Pages 508-515

  Hagiwara, May ^a   Oglesby, Alan ^b   Chung, Karen ^b   Zilber, Sophia ^a   Delea, Thomas E ^a  

^a POLICY ANALYSIS INC PAI   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PROSTATE CANCER; RETROSPECTIVE STUDY;

EID: 83055160765     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(12)70101-8     Document Type: Article

References (19)

1. American Cancer Society. Prostate cancer. What are the key statistics about prostate cancer? http://www.cancer.org/docroot/CRI/ content/CRI_2_4_1X_What_are_the_key_ statistics_for_prostate_cancer_36.asp. Last medical review November 22, 2010. Accessed August 3, 2011.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 suppl): 1588-1594.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
4. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
5. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004;67:390-396.
6. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-347.
7. Delea TE, McKiernan JM, Brandman J, Sung J, Raut M, Oster G. Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumors [abstract]. J Clin Oncol 2005;23[S16]:8094.
8. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006;1:571-576.
9. Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-322.
10. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-1007.
11. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-232.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
13. Bureau of Labor Statistics. United States Department of Labor Web site. Consumer Price Index. Medical Care, US City Average. Series Id: CUUR0000SAM. http://www.bls.gov/cpi/home.htm. Accessed April 21, 2010.
14. Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003;157:364-375.
15. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med 1992;11:1825-1839.
16. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-1060.
17. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
18. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
19. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.